Before you agree
to a cuff repair.
Rotator cuff degeneration, shoulder osteoarthritis, and chronic impingement frequently respond to MSC therapy when the tendon is thinned but not fully retracted. The evaluation tells you what you're working with.
Rotator cuff tendinopathy, partial tears, glenohumeral OA, and chronic impingement.
Shoulder tendon response often tracks slightly faster than large-joint OA.
All-in. Ultrasound-guided delivery, IV adjunct, structured follow-up. Actual figure confirmed after evaluation.
Tendon-first thinking
for the shoulder.
The shoulder is mostly soft tissue. Cuff thickness, tear size, and tendon retraction determine whether regenerative therapy is reasonable, or whether surgical repair is the right tool.
Partial-thickness tears, tendinopathy, and early-stage OA often respond. Full-thickness tears with significant retraction generally do not, once the tendon has pulled away from its footprint, biology alone won't reattach it.
We read your MRI before recommending anything. Our floor isn't "let's try." It's "this is a reasonable case."
Partial cuff tears, tendinopathy
Partial-thickness tears, chronic cuff tendinopathy, and refractory impingement.
Glenohumeral OA, labral drift
Early to moderate shoulder OA and post-labral-repair residuals.
Full retracted tears, massive cuff failure
Full-thickness retracted tears and massive cuff tears where structural reattachment is the only real option.
Shoulder conditions
we evaluate.
Rotator cuff
Partial-thickness tears, tendinopathy, and chronic irritation that hasn't resolved with PT or injections.
- Partial-thickness < 50%
- Chronic tendinopathy
- Post-PRP non-responders
Glenohumeral OA
Early to moderate OA of the GH joint where cartilage wear hasn't progressed to bone-on-bone.
- Grade II–III preferred
- Intact glenoid
- Preserved cuff function
Impingement & labrum
Chronic subacromial impingement and labral degeneration where conservative care has plateaued.
- Refractory impingement
- Labral fraying
- Post-arthroscopy residuals
Ultrasound-guided
tendon-targeted delivery.
Shoulder injections require precision against a moving tendon. Every delivery is done under ultrasound guidance with the cells placed at or adjacent to the target structure.
Allogeneic MSCs, passage three, delivered to the cuff footprint, GH joint, or subacromial space depending on pathology. Dose calibrated per structure.
Procedure runs under local anesthetic. Most patients can use the arm for light activity within 48 hours.
MRI review
Cuff thickness, tear characterization, and joint status evaluated by attending.
Target map
Cuff footprint vs. intra-articular vs. subacromial, matched to pathology.
Ultrasound-guided injection
Live needle visualization. Cell release confirmed at target.
Systemic IV
Supporting systemic anti-inflammatory dose in the infusion suite.
30 / 60 / 90 days
SPADI and VAS tracked. Repeat imaging as indicated.
What to expect.
No promises.
Settling phase
Post-injection soreness resolves. Baseline function largely unchanged.
Function returns
Range of motion, overhead activity, and sleep typically improve first.
Peak window
Best-achieved outcomes with strength and load tolerance.
Durability
Many patients hold improvement with ongoing conditioning. Booster at six months for subset.
Shoulder outcomes track faster than hip or spine, but the same principle holds: no meaningful change is expected in the first two weeks. We measure on standardized scales, not day-to-day feel.
If your cuff has fully retracted off the footprint or you have a massive tear pattern, MSC therapy will not reattach the tendon. We will refer you to a surgeon we trust when that's the case.
Shoulder-specific
questions.
Q.01Will MSCs heal a rotator cuff tear?
Q.02What's the difference between PRP and MSC therapy for shoulder?
Q.03Can I still lift after this?
Q.04What about frozen shoulder?
Other joint regions
we treat.
Start with a
read of your MRI.
A shoulder consult is a physician telling you plainly whether MSC therapy fits your case, or whether repair is what the structure actually needs.